Director Lee Rauch resigns from Ensysce board over severance package dispute

Ensysce Biosciences, Inc.

Lee Rauch resigned effective March 24, 2026, citing disagreement with board-approved severance packages.
Packages provide up to $205,475 in potential severance for CFO and three managers during strategic review.
CFO retention package increased from 6 to 9 months; packages contingent on non-retention in any strategic deal.
Board approved packages on March 27, 2026; Rauch had previously expressed other disagreements.
Company continues evaluating strategic alternatives for its business.

item 5.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-26-013314
form_type: 8-K
ticker: ENSC
cik: 0001716947
company_name: Ensysce Biosciences, Inc.
filed_at: 2026-03-30T23:59:59+00:00
discovered_at: 2026-05-14T18:02:35.988477+00:00
generated_at: 2026-05-15T08:24:19.269498+00:00
sec_items: ["5.02", "9.01"]
event_type: other_material
sentiment: negative
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-26-013314
json_url: https://secwatch.observer/filing/0001493152-26-013314.json
markdown_url: https://secwatch.observer/filing/0001493152-26-013314.md
text_url: https://secwatch.observer/filing/0001493152-26-013314.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315226013314/0001493152-26-013314-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315226013314/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001493152-26-013314

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.